The sulfasalazine market comprises oral medications containing sulfasalazine that are used to treat inflammatory bowel diseases (IBD) such as ulcerative colitis and some types of arthritis like rheumatoid arthritis. Sulfasalazine contains two components—sulfapyridine and 5-aminosalicylic acid. While sulfapyridine helps suppress the immune system, 5-aminosalicylic acid reduces inflammation in the digestive tract. Sulfasalazine works by blocking the inflammation-causing compounds in the body.

The global sulfasalazine market is estimated to be valued at US$ 2.32 Bn in 2024 and is expected to exhibit a CAGR of 18.% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the sulfasalazine market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptagen LLC, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. The global market for sulfasalazine offers lucrative growth opportunities with increasing research to develop new formulations and combination therapies for treating IBD. Major players are expanding their sulfasalazine product offerings globally across Asia Pacific, Europe, and North America.

Market Drivers and Restraints

Increasing prevalence of IBD such as Crohn's disease and ulcerative colitis is a major factor driving the growth of the Sulfasalazine Market Trends. According to recent studies, over 10 million people globally suffer from IBD. Rising adoption of sulfasalazine generics due to their cost-effectiveness compared to expensive biologics is further propelling the market growth. However, stringent regulations for drug approval and side effects associated with long-term usage of sulfasalazine such as nausea, vomiting, and skin rashes are some of the factors hindering the market growth.

Get More Insights on- Sulfasalazine Market